Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotinib PK in Hepatic Impairment
NCT05048368Phase 1Withdrawn
- Sponsor
- Sunshine Lake Pharma
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of larotinib in esophageal cancer and solid tumor (4 cohorts), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Observed Plasma Concentration and Area Under Curve From 0 to Infinity. Planned start Oct 2026; status: withdrawn.
02
Drugs
larotinib
03
Conditions
esophageal cancersolid tumor
Beyond the preview
Go deeper on NCT05048368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048368.